Transvenous Catheter-Based Thrombolysis With Continuous Tissue Plasminogen Activator Infusion for Refractory Thrombosis in a Patient With Behcet’s Disease

Arif, Saeed; Arif, Shaheer; Liaqat, Jahanzeb; Slehria, Atiq-Ur-Rehman; Palwa, Abdur Rahim

doi:10.7759/cureus.10049

Cited by 3 publications

(3 citation statements)

References 10 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The usage, dosage, and side effects of these three drugs have been well studied ( 22 ). Alteplase, also known as recombinant human tissue plasminogen activator, rt-PA, is a thrombolytic agent primarily used for the treatment of Behcet’s disease-related thrombosis ( 23 ). However, the role of omeprazole, rabeprazole, and celastrol in BD has not been studied.…”

Section: Resultsmentioning

confidence: 99%

“…To explore potential drugs, we analyzed the association between genes or drugs and the top 3 hub genes through the DGIdb database. Our results were centered on seven drugs, including IFX, pentoxifylline, and cyclosporine, which are clinically appropriate for the treatment of BD, and alteplase can be used for the treatment of BD complications ( 22 , 23 ). However, the remaining three drugs have not been proven to be effective in the treatment of BD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Candidate Drugs Screening for Behcet’s Disease Based on Bioinformatics Analysis and Mouse Experiments

Xia¹,

Lyu²,

Li³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundBehcet’s disease (BD) is a chronic immune disease that involves multiple systems. As the pathogenesis of BD is not clear, and new treatments are needed, we used bioinformatics to identify potential drugs and validated them in mouse models.MethodsBehcet’s disease-related target genes and proteins were screened in the PubMed and UVEOGENE databases. The biological functions and pathways of the target genes were analyzed in detail by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. A protein-protein interaction (PPI) network was constructed by the STRING database, and hub genes were identified by the Cytoscape plug-in CytoHubba. Gene-drug interactions were identified from the DGIdb database. Experimental autoimmune uveitis (EAU) mice were used as an animal model for drug validation.ResultsA total of 249 target genes and proteins with significant differences in BD were screened, and the results of functional enrichment analysis suggested that these genes and proteins were more located on the cell membrane, involved in regulating the production of cytokines and affecting the activity of cytokines. They mainly regulated “Cytokine- Cytokine receptor interaction”, “Inflammatory bowel disease (IBD)” and “IL-17 signaling Pathway”. In addition, 10 hub genes were obtained through PPI network construction and CytoHubba analysis, among which the top 3 hub genes were closely related to BD. The DGIdb analysis enriched seven drugs acting together on the top 3 hub genes, four of which were confirmed for the treatment of BD or its complications. There is no evidence in the research to support the results in omeprazole, rabeprazole, and celastrol. However, animal experiments showed that rabeprazole and celastrol reduced anterior chamber inflammation and retinal inflammation in EAU mice.ConclusionsThe functional analysis of genes and proteins related to BD, identification of hub genes, and validation of potential drugs provide new insights into the disease mechanism and potential for the treatment of BD.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Candidate Drugs Screening for Behcet’s Disease Based on Bioinformatics Analysis and Mouse Experiments

Xia¹,

Lyu²,

Li³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Anticoagulants may be added, but only for a short time ( 2 ). It is reported recently that a patient with CVST related to BD came with headaches and vision changes that was resolved after 5 sessions of plasmapheresis along with steroids and anticoagulation, which provides another alternative option of treatment ( 3 ). In acute deep venous thrombosis other than CVST, glucocorticoids and immunosuppressants such as cyclophosphamide are recommended, and anticoagulants may be added provided that coexistent pulmonary artery aneurysms are ruled out ( 2 ).…”

Section: Discussionmentioning

confidence: 99%

Case Report: Catheter-Directed Endovascular Thrombolysis for Refractory Cerebral Venous Sinus Thrombosis in a Patient With Behçet Disease

Qiu

2021

Front. Neurol.

View full text Add to dashboard Cite

Background: Behçet disease (BD) is an autoimmune and vasculitic disorder. BD affects the veins more frequently than the arteries. The cerebral venous sinus thrombosis (CVST) was reported to occur in about 20% of neuro-BD. Huge dilemma exists in the treatment of CVST with BD, some of which were refractory to the standard therapy.Case Presentation: Here, we report a BD case with refractory intracranial hypertension caused by CVST which is successfully treated with catheter-directed endovascular thrombolysis. Before endovascular thrombolysis, intravenous pulse methylprednisolone combined with anticoagulant therapy was used, and resulted in limited effects.Conclusion: We conclude that catheter-directed thrombolysis may be considered for refractory CVST with BD, provided that coexistent pulmonary and cerebral artery aneurysms are ruled out.

show abstract

Need for Swift Diagnosis of Primary Angiitis of Central Nervous System: A Case With Focal Motor Seizures of Hand Progressing to Aphasia

Arif

Liaqat

et al. 2020

Cureus

Self Cite

View full text Add to dashboard Cite

Primary angiitis of the central nervous system (PACNS) is a rare disorder and difficult to diagnose. The time period from the presentation of the patient until a diagnosis can be protracted, which may result in further progression of the disease and poor patient outcomes. It has immensely varied symptomatology, further confounding swift diagnosis. We present a case of a 33-year-old male who had focal motor seizures with intact awareness of the right upper limb for three weeks prior to presenting to our hospital with acute right hemiparesis. One month into hospital admission, the patient developed complete motor aphasia while being investigated for the cause of multiple ischemic brain infarcts. The patient underwent immunosuppression along with plasmapheresis and pulse steroid therapy started prophylactically on suspicion of PACNS, which was subsequently confirmed by brain biopsy. Disease remission was achieved with rituximab.

show abstract

Transvenous Catheter-Based Thrombolysis With Continuous Tissue Plasminogen Activator Infusion for Refractory Thrombosis in a Patient With Behcet’s Disease

Cited by 3 publications

References 10 publications

Candidate Drugs Screening for Behcet’s Disease Based on Bioinformatics Analysis and Mouse Experiments

Candidate Drugs Screening for Behcet’s Disease Based on Bioinformatics Analysis and Mouse Experiments

Case Report: Catheter-Directed Endovascular Thrombolysis for Refractory Cerebral Venous Sinus Thrombosis in a Patient With Behçet Disease

Need for Swift Diagnosis of Primary Angiitis of Central Nervous System: A Case With Focal Motor Seizures of Hand Progressing to Aphasia

Contact Info

Product

Resources

About